<DOC>
	<DOCNO>NCT01756261</DOCNO>
	<brief_summary>The objective survey evaluate effectiveness EYLEA Quality Life ( QOL ) . The QOL evaluate use Japanese version ( v.1.4 - interviewer administer format ) National Eye Institute Visual Function Questionnaire-25 ( NEI VFQ-25 ) compare baseline 6 12 month start EYLEA treatment .</brief_summary>
	<brief_title>EYLEA AMD-QOL ( Age-Related Macular Degeneration-Quality Life ) Post-marketing Surveillance Japan</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>Patients determine start EYLEA treatment Patients register Special drug use investigation EYLEA AMD ( Trial Number 15858 ) Patients agree patient informed consent Patients already receive EYLEA</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>EYLEA</keyword>
	<keyword>Age-Related Macular Degeneration</keyword>
	<keyword>QOL</keyword>
</DOC>